Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Heart. 2018 Sep 18;104(24):1995–2002. doi: 10.1136/heartjnl-2018-313726

Table 5.

Incidence of QT prolongation with TKIs.

TKI Agent Average QT prolongation (ms) Increase in QTc >60ms (%) QTc >500ms (%) Torsades de pointes (%)
Axitinib <10 N/a N/a N/a
Cabozantinib 10-15 N/a N/a N/a
Pazopanib N/a N/a 2 <0.3
Sorafenib 8-13 N/a N/a N/a
Sunitinib 9.6-15.4 1-4 0.5 <0.1
Vandetanib 36 12-15 4.3-8 Described, % N/a